Avalo Therapeutics at Stifel 2026 Healthcare Conference: phase iii ahead
At a glance
- $AVTX today−3.26%last $7.13
- Vs industry peers−2.23 pts6-peer median −1.02% · far behind
- Since Nov 10−0.14%from the first trade after the story
- 52-week range9.2% above low$6.53 – $24.27
- Cash runway~12 mo$65.0M cash ÷ $5.5M/mo burn · 10-Q
- Coverage6 this week20 in 30 days · about its usual pace
- Legal: Filed with SEC
- Clear: key person, regulatory, security, operational, financial integrity
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Legal · SEC 8-K, Item 1.02, Nov 5: Filed: the termination of a material agreement. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: Drugmakers thrive on progress, not profits — late-stage trials are the real currency in this game.
- How the stocks are trading: $AVTX -3.26%, $SF -2.16%, $HR -0.31% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
Avalo Therapeutics ($AVTX) dropped 3.26% to $7.13 in the latest session. Over the past month it is down 38.5%. It now sits 71% under the 52-week high of $24.27 and 9.2% above the year's low of $6.53, close to the bottom of its range. It has been a volatile year: the high was 3.7 times the low, so moves this size are not unusual for it. Stifel Financial ($SF) fell 2.16% to $71.02 in the latest session. Over the past month it is up 7.5%. That leaves it 21% below its 52-week high of $89.83 and 8.6% above its low of $65.40. The high sits 37% above the low, a moderate range for a year.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $AVTX lost $18.9M over the quarter to Sep 30, 2026. Operations used $49.2M of cash over the nine months to Sep 30, 2026 — about $5.5M a month — against $65.0M in cash on Sep 30, 2026. At that pace the cash covers about 12 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $44.9M against $65.0M of cash on Sep 30, 2026. Its most recent filings before this story: 8-K on Nov 5, 2026, 10-Q on Nov 5, 2026, 8-K on Nov 5, 2026. Figures are as filed with the SEC; the $AVTX page has the full statements.
How much coverage it is getting
This is one of 20 stories on these companies in Wook's last 30 days of coverage, including 6 this week. That is a little busier than usual: over the month it has averaged about 5 a week. Going by their wording, 25% read bullish, 75% neutral and 0% bearish. This one reads neutral too, in line with most of them. Investing.com wrote 11 of the 20 (55%), so the count reflects one outlet's output more than broad attention.
The bigger picture
Healthcare moves on deadlines and decisions — a trial result can shift a stock, while a policy tweak can shake the whole sector. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The $AVTX page has the full chart, filings, and valuation model — comparing how outlets frame the same story is the quickest way to spot the facts. Wook AI can pull live data and run the numbers on request — how far $AVTX is from its high, or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 10, 2026. $AVTX has moved -0.14% ($7.14 to $7.13), $SF has moved -2.87% ($73.12 to $71.02) and $HR has moved -0.47% ($19.35 to $19.26). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
